Figures & data
Table 1. Demographics and clinical characteristics of the study population.
Figure 1. Survival analysis of the antibiotic-to-delivery interval according to the antibiotic regimen. Patients who received regimen 2 (ceftriaxone, clarithromycin, and metronidazole) had a significantly longer median antibiotics-to-delivery interval than those who received regimen 1 (ampicillin and/or cephalosporins, in some patients other antibiotics were combined with them.) [median (interquartile) 23 d (10–51 d) versus 12 d (5–52 d), p < 0.01], which remained significant after adjusting for gestational age at the time of the initiation of antibiotic therapy, the presence of intra-amniotic infection/inflammation, and antenatal corticosteroid administration (hazards ratio 0.69, 95% (CI) 0.49–0.96; p < 0.05 by Cox proportional hazards model analysis).
![Figure 1. Survival analysis of the antibiotic-to-delivery interval according to the antibiotic regimen. Patients who received regimen 2 (ceftriaxone, clarithromycin, and metronidazole) had a significantly longer median antibiotics-to-delivery interval than those who received regimen 1 (ampicillin and/or cephalosporins, in some patients other antibiotics were combined with them.) [median (interquartile) 23 d (10–51 d) versus 12 d (5–52 d), p < 0.01], which remained significant after adjusting for gestational age at the time of the initiation of antibiotic therapy, the presence of intra-amniotic infection/inflammation, and antenatal corticosteroid administration (hazards ratio 0.69, 95% (CI) 0.49–0.96; p < 0.05 by Cox proportional hazards model analysis).](/cms/asset/1d418147-4058-4fb6-b167-f1d2858ad18b/ijmf_a_1020293_f0001_c.jpg)
Table 2. Pregnancy outcomes of the study population according to the regimen of antibiotics used.
Table 3. Neonatal outcomes of the study population according to the regimen of antibiotics used.
Table 4. Perinatal outcomes of patients without intra-amniotic infection/inflammation according to the regimen of antibiotics used.
Table 5. Perinatal outcomes of patients with intra-amniotic infection/inflammation according to the regimen of antibiotics used.
Figure 2. Survival analysis of the antibiotic-to-delivery interval according to the antibiotic regimen in patients with intra-amniotic infection/inflammation at the time of amniocentesis. A significant longer antibiotic-to-delivery interval was observed in patients with intra-amniotic infection/inflammation who received antibiotic regimen 2 (ceftriaxone, clarithromycin, and metronidazole) than in those who received antibiotic regimen 1 (ampicillin and/or cephalosporins, in some patients other antibiotics were combined with them) [median (interquartile) 29 d (10–60 d) versus 5 d (2–14 d), p < 0.001]. Multivariate survival analysis using the Cox proportional hazards model analysis also demonstrated the longer antibiotic-to-delivery interval in patients who received antibiotic regimen 2 than in those who received regimen 1 after adjusting for gestational age at the time of initiation of antibiotic treatment and antenatal corticosteroid administration (hazards ratio 0.41, 95% CI 0.27–0.63; p < 0.001).
![Figure 2. Survival analysis of the antibiotic-to-delivery interval according to the antibiotic regimen in patients with intra-amniotic infection/inflammation at the time of amniocentesis. A significant longer antibiotic-to-delivery interval was observed in patients with intra-amniotic infection/inflammation who received antibiotic regimen 2 (ceftriaxone, clarithromycin, and metronidazole) than in those who received antibiotic regimen 1 (ampicillin and/or cephalosporins, in some patients other antibiotics were combined with them) [median (interquartile) 29 d (10–60 d) versus 5 d (2–14 d), p < 0.001]. Multivariate survival analysis using the Cox proportional hazards model analysis also demonstrated the longer antibiotic-to-delivery interval in patients who received antibiotic regimen 2 than in those who received regimen 1 after adjusting for gestational age at the time of initiation of antibiotic treatment and antenatal corticosteroid administration (hazards ratio 0.41, 95% CI 0.27–0.63; p < 0.001).](/cms/asset/d4113f25-3074-4186-8414-84cfd82c1963/ijmf_a_1020293_f0002_c.jpg)